AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Mesothelioma: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaNCT04334759 · results posted 2026-10-01 · PrECOG, LLC. · 214 people · tests Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural MesotheliomaNCT03762018 · results posted 2026-05-14 · ETOP IBCSG Partners Foundation · 400 people · tests Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab

Want these every week? Follow mesothelioma and get a note on your phone with the new trials and papers.

🔔 Follow mesothelioma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy